Literature DB >> 1315995

Small cell carcinoma of prostate: effectiveness of hormonal versus chemotherapy.

S R Moore1, Y Reinberg, G Zhang.   

Abstract

Small cell carcinoma of the prostate is rare and associated with a rapidly fatal course. Since 1977, 47 cases have been reported in the world literature with data from 3 additional cases presented herein. The purpose of our review was to determine the effectiveness of hormonal versus chemotherapy. Thirty-four of the 50 cases have known clinical histories. Four patients were not treated, and all were dead of their disease within an average of 2.75 months. Six patients were eliminated from our review because small cell carcinoma was discovered at autopsy. Another 5 cases were omitted because hormonal +/- chemotherapy had already been given for a previous diagnosis of adenocarcinoma, but no specific therapy was given once the small cell carcinoma developed. Of the remaining 19 cases, only 2 have survived. One is still alive forty-three months after hormonal treatment, and another is alive with disease six months after the initiation of hormonal therapy and chemotherapy. Five patients were given hormonal therapy only, and none of them responded. In 4 patients chemotherapy was given after hormonal therapy had failed, and they too died of their disease within a short period of time. However, an additional 8 patients were treated with immediate chemotherapy +/- hormonal therapy and had substantially longer clinical remissions. Therefore, although small cell carcinoma is a uniformly fatal disease, immediate chemotherapy should be considered to promote better clinical remissions.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1315995     DOI: 10.1016/0090-4295(92)90235-o

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  16 in total

1.  Complete remission in a patient with metastatic mixed adenocarcinoma/extrapulmonary small cell carcinoma of the prostate.

Authors:  Jonathan Edward Brammer; Premal Lulla; Garrett Rush Lynch
Journal:  Int J Clin Oncol       Date:  2011-02-24       Impact factor: 3.402

2.  Differentially methylated genes and androgen receptor re-expression in small cell prostate carcinomas.

Authors:  Brittany Kleb; Marcos R H Estécio; Jiexin Zhang; Vassiliki Tzelepi; Woonbok Chung; Jaroslav Jelinek; Nora M Navone; Salahaldin Tahir; Victor E Marquez; Jean-Pierre Issa; Sankar Maity; Ana Aparicio
Journal:  Epigenetics       Date:  2016-02-18       Impact factor: 4.528

3.  Neuroendocrine prostate cancer xenografts with large-cell and small-cell features derived from a single patient's tumor: morphological, immunohistochemical, and gene expression profiles.

Authors:  Nora M Navone; Sankar N Maity; Ana Aparicio; Vasiliki Tzelepi; John C Araujo; Charles C Guo; Shoudan Liang; Patricia Troncoso; Christopher J Logothetis
Journal:  Prostate       Date:  2010-11-17       Impact factor: 4.104

4.  ERG gene rearrangements are common in prostatic small cell carcinomas.

Authors:  Tamara L Lotan; Nilesh S Gupta; Wenle Wang; Antoun Toubaji; Michael C Haffner; Alcides Chaux; Jessica L Hicks; Alan K Meeker; Charles J Bieberich; Angelo M De Marzo; Jonathan I Epstein; George J Netto
Journal:  Mod Pathol       Date:  2011-02-18       Impact factor: 7.842

5.  Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma.

Authors:  Hsueh-Li Tan; Akshay Sood; Hameed A Rahimi; Wenle Wang; Nilesh Gupta; Jessica Hicks; Stacy Mosier; Christopher D Gocke; Jonathan I Epstein; George J Netto; Wennuan Liu; William B Isaacs; Angelo M De Marzo; Tamara L Lotan
Journal:  Clin Cancer Res       Date:  2013-12-09       Impact factor: 12.531

6.  Combined chemotherapy with carboplatin plus irinotecan showed favorable efficacy in a patient with relapsed small cell carcinoma of the prostate complicated with meningeal carcinomatosis.

Authors:  Tadaaki Yamada; Koushiro Ohtsubo; Hisatsugu Mouri; Kaname Yamashita; Kazuo Yasumoto; Kouji Izumi; Yoh Zen; Hiroyuki Watanabe; Seiji Yano
Journal:  Int J Clin Oncol       Date:  2009-10-25       Impact factor: 3.402

7.  Patterns of Cancer Progression of Metastatic Hormone-sensitive Prostate Cancer in the ECOG3805 CHAARTED Trial.

Authors:  Alan H Bryce; Yu Hui Chen; Glenn Liu; Michael A Carducci; David M Jarrard; Jorge A Garcia; Robert Dreicer; Maha Hussain; Mario Alfredo Eisenberger; Elizabeth R Plimack; Nicholas J Vogelzang; Robert S DiPaola; Lauren Harshman; Christopher J Sweeney
Journal:  Eur Urol Oncol       Date:  2020-08-15

8.  Small cell carcinoma of the prostate treated with amrubicin.

Authors:  Manabu Katou; Norihito Soga; Takehisa Onishi; Kiminobu Arima; Yoshiki Sugimura
Journal:  Int J Clin Oncol       Date:  2008-05-08       Impact factor: 3.402

Review 9.  Small cell carcinoma of the prostate.

Authors:  Rosa Nadal; Michael Schweizer; Oleksandr N Kryvenko; Jonathan I Epstein; Mario A Eisenberger
Journal:  Nat Rev Urol       Date:  2014-02-18       Impact factor: 14.432

10.  Platinum-based chemotherapy for variant castrate-resistant prostate cancer.

Authors:  Ana M Aparicio; Andrea L Harzstark; Paul G Corn; Sijin Wen; John C Araujo; Shi-Ming Tu; Lance C Pagliaro; Jeri Kim; Randall E Millikan; Charles Ryan; Nizar M Tannir; Amado J Zurita; Paul Mathew; Wadih Arap; Patricia Troncoso; Peter F Thall; Christopher J Logothetis
Journal:  Clin Cancer Res       Date:  2013-05-06       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.